News & Events

20 September 2021

Successful 2nd GA Meeting

Congrats to all work package leaders for the great progress made on their tasks, and for the detailed updates and presentations during the 2nd Steering Committee (SC) Meeting on 20 September 2021. The preparations for getting 30 European liver centres on board, receiving all necessary ethics approvals, and setting up the clinical trial (including manufacturing the drugs for the combinatorial G-TAK therapy) are at full speed. Although we had lots of fun on Zoom, we still can't wait to meet in person soon. Hopefully, for the 2nd General Assembly (GA) meeting next year!

2 September 2021

Cornelius Engelmann introduces A-TANGO on YouTube

Watch this introductory video about A-TANGO. It is a recording of a joint patient event that informed the liver patient community in Europe about A-TANGO and two related Horizon 2020-funded cirrhosis projects, namely DECISION and MICROB-PREDICT. At the beginning of the video, the project's scientific coordinator, Prof. Dr. Rajiv Jalan, emphasises the urgent need of novel therapies for late-stage cirrhosis, before the clinical study supervisor, Dr. Cornelius Engelmann, explains the details of the new combinatorial therapy 'G-TAK' that A-TANGO tests.

27 August 2021

Invitation to join the Liver Health Helix

The 'Helix' will form a community hub of peers that allows you to collaborate and also follow the A-TANGO project's progress, activities, and results. Within the Helix, you can share and join specific collaboration opportunities related to cirrhosis, ACLF, and liver health. You can also invite stakeholders outside of the network who may be interested in this field. Join the Liver Health Helix and click "Follow". You will then be notified of new opportunities according to your chosen interests.

OUR VISION

More than 10 million people worldwide suffer from decompensated cirrhosis, often as a result of severe alcoholic hepatitis (sAH) or other chronic liver diseases. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterized by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy G-TAK. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.

Read more

OBJECTIVES

  • Obtain ethical and regulatory approval of the planned clinical studies
  • Ensure safe and regulated supply of the required drugs and placebos
  • European multicenter clinical study to establish the safety, pharmacokinetics, and efficacy of our novel therapeutic strategy
  • Explore the pathophysiological mechanisms and evaluate biomarkers
  • Evaluate our results with respect to clinical outcome, treatment impact, and quality of life
  • Exploit our results by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
  • Disseminate the therapeutic potential of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

Read more

SCIENTIFIC COORDINATOR

Prof. Dr. Rajiv Jalan (EFCLIF)
Travessera de Gràcia 11, 7th floor
08021 Barcelona
Spain

CLINICAL STUDY SUPERVISOR

Dr. med. Cornelius Engelmann (Charité)
Augustenburger Platz 1
13353 Berlin
Germany

PROJECT
MANAGEMENT

concentris research management gmbh
Ludwigstr. 4
82256 Fürstenfeldbruck
Germany